Oscotec Inc.

Translating science into medicine
Sign Up
PRESS
FLT3/AXL Inhibitor (A... 2020.06.22  
  1. No Image 01Jun
    by

    YH25448, a 3rd Generation EGFR-TKI, in Patients with EGFR-TKI-resistant NSCLC: Phase I/II Study Results

  2. No Image 01Jun
    by

    YH25448, a 3rd generation EGFR-TKI, in patients with EGFR-TKI-resistant NSCLC: Phase I/II study results

  3. No Image 01Jun
    by

    YH25448, an irreversible 3rd-generation EGFR TKI, exhibits superior anticancer effects with potent brain BBB penetration in NSCLC

  4. No Image 01Jun
    by

    Superior Efficacy and Selectivity of Novel Small-Molecule Kinase Inhibitors of T790M-Mutant EGFR in Preclinical Models of Lung Cancer

  5. No Image 01Jun
    by

    YH25448, a highly selective 3rd generation EGFR TKI, exhibits superior survival benefit over osimertinib in mice with brain metastases of NSCLC

  6. No Image 01Jun
    by

    Crystal structures of spleen tyrosine kinase in complex with novel inhibitors: structural insights for design of anticancer drugs

  7. No Image 01Jun
    by

    Highly potent and selective pyrazolylpyrimidines as Syk kinase inhibitors

  8. No Image 01Jun
    by

    G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia

  9. No Image 01Jun
    by

    Crystal Structure of Pim1 Kinase in Complex with a Pyrido[4,3-D]Pyrimidine Derivative Suggests a Unique Binding Mode

Board Pagination Prev 1 Next
/ 1
© k2s0o1d6e0s8i2g7n. ALL RIGHTS RESERVED.
Requesting to the server, please wait.